This report was first published by Endpoints News. To see the original version, click here
SAN DIEGO — Since Herceptin’s approval in 1998, breast cancer has been reshaped from a near-term death sentence into — in many cases — a chronic disease. Now, researchers hope daraxonrasib from Revolution Medicines will launch the same type of transformation in pancreatic cancer.
A recent Phase 3 finding on daraxonrasib “is one of the most important things that’s happened in cancer therapeutics in the last 30 to 40 years,” Stifel healthcare director Tim Opler said. “This is very much a Herceptin-type moment.”
您已阅读13%（603字），剩余87%（4193字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。